Advertisement

Topics

Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions

16:01 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- Preclinical results show potential first-in-class disease-modifying properties of sotatercept in pulmonary arterial hypertension - - Company expects to initiate a Phase 2 trial in 1H 2018 - Acceleron Pharma Inc. (...

Other Sources for this Article

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
Or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
Or
Media:
BMC Communications
Brad Miles, 646-513-3125

NEXT ARTICLE

More From BioPortfolio on "Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...